Gregg Fields, Ph.D., Interim Vice President for Research (Photo by Alex Dolce)

The United States Department of State’s Bureau of Educational and Cultural Affairs (ECA) has selected Gregg Fields, Ph.D., Florida Atlantic University’s interim vice president for research, as a Fulbright Specialist Program grantee following a competitive application process.

The Fulbright Specialist Program, part of the larger Fulbright Program, was established in 2001 by the ECA. The program pairs highly qualified U.S. academics and professionals with host institutions abroad to share their expertise, strengthen institutional linkages, hone their skills, gain international experience, and learn about other cultures while building capacity at their overseas host institutions.

Fulbright Specialists engage in two- to six-week, project-based exchanges at host institutions across the globe and the selected project is based on the grantee’s expertise and the needs of the receiving country.

Fields’ extensive experience in research, education and international collaboration positions him as an ideal grantee of the Fulbright Specialist Program. His unique expertise and dedication to advancing medical science has contributed to global scientific and educational communities, sharing his knowledge and fostering international partnerships in the quest to improve disease discovery and treatment.

“Being awarded the Fulbright Specialist Program is an immense honor and privilege for me. It signifies not only recognition of my contributions and expertise in my field but also an incredible opportunity to contribute to global knowledge exchange and collaboration,” said Fields. “Receiving this award will enable me to engage with diverse cultures, share insights and foster mutual understanding, ultimately advancing academic and professional networks worldwide.”

In the realm of innovative medical science, few researchers are as distinguished as Fields, whose career seamlessly blends biology, chemistry and groundbreaking treatment strategies. His extensive background in chemistry, which include both B.S. and Ph.D. degrees, has helped to advance specialization in pharmaceutical chemistry. Fields is highly regarded for developing therapeutic agents, and his research has significantly advanced the understanding of disease progression and treatment, particularly in the fields of matrix metalloproteinases (MMPs) and magnetic resonance-guided focused ultrasound (MRgFUS).

MMPs are a group of enzymes that play crucial roles in the remodeling and degradation of the extracellular matrix (ECM), which is the network of proteins and other molecules outside cells that provides structural and biochemical support. Research into MMPs continues to reveal their complex roles in health and disease, making them a significant focus of biomedical research.

Fields’ work on MMPs, critical to various pathologies, has been notably pioneering. His laboratory has dedicated more than three decades to developing selective MMP inhibitors, with a focus on diseases such as rheumatoid arthritis and neurodegenerative disorders such as multiple sclerosis and Alzheimer’s disease (AD). These inhibitors are designed to target specific MMPs, offering new hope for patients suffering from these debilitating conditions. Fields’ laboratory research has provided valuable insights into the structural and chemical elements that contribute to the effectiveness of these inhibitors.

In addition to his work on MMP inhibitors, Fields is at the forefront of clinical trials involving MRgFUS, a revolutionary technology that opens the blood-brain barrier. This approach significantly improves drug delivery to the brain and holds promise for treating a range of brain disorders, including AD, brain cancers, and even drug addiction. MRgFUS could dramatically enhance the efficacy of treatments targeted at the brain, offering new avenues for managing complex neurological conditions.

Fields is also a dedicated educator and international collaborator who has delivered more than 280 lectures and has taught numerous courses, including biochemistry, medicinal chemistry and chemical biology. His global influence is reflected in invitations to speak at prestigious institutions and conferences worldwide. From the Carlsberg Laboratory in Denmark to Imperial College London and the Karolinska Institutet in Stockholm, Fields has shared his expertise with a broad audience.

Fulbright Specialists, who represent a wide range of professional and academic disciplines, are competitively selected to join the Fulbright Specialist Roster based on their knowledge, skill sets and ability to make a significant contribution to projects overseas. Those individuals who have been approved to join the Fulbright Specialist Roster are then eligible to be matched with approved projects designed by foreign host institutions from more than 150 countries. Once abroad, specialists partner with their host institution to conduct project activities in support of the host institution’s priorities and goals.

The program encompasses a wide array of disciplines, including science, technology, education, business and the arts. By bringing in specialists, institutions benefit from their advanced knowledge and skills, which can enhance various aspects of their work, such as research, curriculum development or program implementation.

The impact of the Fulbright Specialist Program extends beyond immediate project goals. It fosters international collaboration and enhances mutual understanding between the U.S. and other countries. For specialists, it offers valuable international experience and opportunities to build professional networks while contributing to global development and knowledge exchange.

-FAU-